Aditxt, Inc..
ADTX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Aditxt, Inc. is a biotechnology company focused on developing and commercializing technologies specifically designed to improve the health of the immune system. The company is involved in developing allogeneic cell therapies for the treatment of diseases. Aditxt's key focus areas include immune moni...Show More
Better Health for All
20
Aditxt, Inc.'s core business is focused on developing technologies to improve immune system health. Its subsidiary, Pearsanta, received IRB approval from WCG Clinical to initiate a clinical study for the Mitomic® Endometriosis Test (MET), a blood-based diagnostic.
1
This diagnostic aims to reduce the current 7 to 10-year delay in endometriosis diagnosis.
2
The clinical study, which plans to enroll up to 1,000 patients starting in May 2025, is registered on ClinicalTrials.gov under identifier NCT06907550.
3
No evidence of harmful products or activities was found.
4
Fair Money & Economic Opportunity
0
Aditxt, Inc. is a biotechnology company focused on immune system health and early cancer detection.
1
The provided articles detail its scientific endeavors, financial performance, and corporate strategies, including a Bitcoin-backed treasury strategy and planned IPOs for subsidiaries.
2
However, there is no evidence in any of the articles that Aditxt, Inc. operates as a financial institution, offers lending or deposit services to consumers, or engages in any activities related to financial inclusion or economic opportunity for underserved populations.
3
Therefore, all KPIs under the 'Fair Money & Economic Opportunity' value are omitted as there is no specific, concrete data point to assess them against the rubric's thresholds.
4
Fair Pay & Worker Respect
0
Aditxt, Inc. had 26 employees as of December 31, 2024.
1
Executive compensation details are available for several officers for 2021 and 2022; for instance, CEO Amro Albanna's 2022 salary was $500,000.
2
The company has adopted a code of business conduct and ethics and corporate governance guidelines.
3
However, no specific data was provided regarding living wage coverage, CEO-to-median employee pay ratio, collective bargaining agreements, safety incident rates, pay equity ratios, worker engagement scores, employee turnover rates, labor violation incidents, the share of insecure contracts, or health insurance coverage for the general workforce.
Fair Trade & Ethical Sourcing
0
The provided articles focus on Aditxt, Inc.'s business model, programs, planned initiatives, and details of a private placement for securities.
1
2
3
No information or specific data points related to fair trade certifications, supply chain audits, forced or child labor incidents, traceability coverage, remediation speed for violations, ethical sourcing clauses in contracts, materials risk, or supplier diversity spend were found in any of the provided documents.
4
5
6
Honest & Fair Business
0
No evidence available to assess Aditxt, Inc. on Honest & Fair Business.
Kind to Animals
-70
The company uses animal models for non-clinical and preclinical studies, including in mice and pigs, for conditions such as skin transplantation, psoriasis, type 1 diabetes, and alopecia areata.
1
There is no evidence that the company employs any validated non-animal testing methods. The company's practice involves using animals for product testing and preclinical studies, with no formal policy or commitment to reduce or restrict animal testing explicitly stated.
2
In one study, animals were administered ADi™ once a week for 8 weeks, with 80% showing a durable response for the entire 40-week study period.
3
Another preclinical efficacy study in NOD mice lasted over 300 days, with 70% showing hyperglycemia prevention.
4
The FDA is phasing out animal testing requirements for some drugs, but this is a regulatory change and not a company-specific action by Aditxt.
5
No War, No Weapons
0
Aditxt, Inc. is a biotechnology company focused on developing technologies to improve immune system health, early cancer detection, neurological diagnostics, and reproductive health.
1
Its patents are focused on reprogramming the immune system.
2
The provided articles contain no evidence of the company's involvement in arms manufacturing, military contracts, dual-use technologies with military applications, sales to sanctioned regimes, or any other activities related to war or weapons. Therefore, all KPIs are scored as 0, indicating that these activities are not applicable to the company's core business operations.
Planet-Friendly Business
0
No specific, concrete data points related to planet-friendly business metrics, environmental performance, or sustainability initiatives for ADTX.US were found in the provided articles.
1
The articles explicitly state that sustainability data is unavailable or that no relevant ESG metrics are provided.
2
Respect for Cultures & Communities
0
The provided articles focus on Aditxt, Inc.'s business strategy, financial updates, shareholder meetings, and subsidiary progress. No specific, concrete data points or information regarding the company's engagement with local or indigenous communities, cultural impact assessments, community investments, cultural appropriation incidents, or related social responsibility metrics were found. Therefore, no KPIs under 'Respect for Cultures & Communities' can be scored based on the evidence provided.
Safe & Smart Tech
0
The provided articles do not contain any specific, concrete data points or facts related to data protection, cybersecurity, responsible AI, or digital rights stewardship for Aditxt, Inc. or its subsidiaries. Information regarding regulatory compliance and certifications pertains to medical product development and laboratory quality standards (e.g., FDA, German regulatory agency, CLIA/CAP).
1
,
2
,
3
, not privacy or security regulations (e.g., GDPR, CCPA) or certifications relevant to digital rights.
Zero Waste & Sustainable Products
-20
Kellanova (ADTX.US) has a company-wide commitment to achieve 100% reusable, recyclable, or compostable packaging by 2030.
1
The company also states its plastic packaging footprint is 12% of its total packaging usage, which it notes is significantly lower than peer food companies.
2
Kellanova is working to redesign packaging to be recyclable or compostable and is reducing packaging usage and removing single-use plastics.
3
It collaborates with various partners and is a signatory to the Ellen MacArthur New Plastics Economy Global Pledge.
4
However, specific quantitative data on current waste diversion rates, product recyclability percentages, recycled content percentages, or the measurable effectiveness of waste reduction initiatives are not provided.
5
The article also notes that current recycled plastic use is low due to limited availability and food safety regulations.
6